CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands	3 Months Ended
	Jul. 02, 2011		Jul. 03, 2010
Cash Flows from Operating Activities:
Net income	$ 16,947		$ 17,918
Non cash items:
Depreciation and amortization	11,988		12,410
Stock compensation expense	2,401		2,197
Loss/(Gain) on sales of property, plant and equipment	56		(15)
Unrealized loss from hedging activities	609		877
Accretion of interest expense on contingent consideration	89		165
Change in operating assets and liabilities:
Decrease in accounts receivable, net	7,939		655
Increase in inventories	(10,288)		(4,167)
Decrease in prepaid income taxes	7,993		6,617
Decrease in other assets and other long-term liabilities	(3,059)		(4,591)
Tax benefit on exercise of stock options	356		538
Decrease in accounts payable and accrued expenses	(7,900)		(19,078)
Net cash provided by operating activities	27,131		13,526
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(11,801)		(15,224)
Proceeds from sale of property, plant and equipment	19		111
Net cash used in investing activities	(11,782)		(15,113)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(361)		(205)
Net decrease in short-term loans	(9)		(9,936)
Employee stock purchase plan	1,849		1,645
Exercise of stock options	2,675		3,010
Excess tax benefit on exercise of stock options	313		549
Share repurchase			(50,000)
Net cash provided by/(used in) financing activities	4,467		(54,937)
Effect of exchange rates on cash and cash equivalents	368		(1,571)
Net Increase/(Decrease) in Cash and Cash Equivalents	20,184		(58,095)
Cash and Cash Equivalents at Beginning of Year	196,707		141,562
Cash and Cash Equivalents at End of Period	216,891	[1]	83,467
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	3,150		1,091
Supplemental Disclosures of Cash Flow Information:
Interest paid	102		128
Income taxes paid	$ 1,387		$ 1,650

[1] (Unaudited)